63 results about "Maculopathy" patented technology

A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

The present invention provides a crystal of a pharmaceutically acceptable salt of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.

Provided are methods, pharmaceutical formulations and kits thereof for the treatment and / or prevention of conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of posterior and / or anterior tissues and fluids of the eye, including conditions associated with proliferative retinopathies, for example, diabetic retinopathy, age-related maculopathy, retinopathy of prematurity, retinopathy associated with macular edema, or retinopathy associated with sickle cell disease, using the topical administration of mecamylamine or a pharmaceutically acceptable salt thereof to the eye. Methods of preparing the pharmaceutical formulations are also provided.

The invention relates to application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment, which is characterized in that digitoflavone-7-O-beta-D-glucuronide can be used as a main active component for preparing a medicine treating the pathological change of the fundus. One kind of or a plurality of kinds of natural or synthetic active components with a synergic or auxiliary action with the digitoflavone-7-O-beta-D-glucuronide can be added for preparing a medicine treating fundus diseases. The digitoflavone-7-O-beta-D-glucuronide is used for treating the diabetic pathological change of the retina, the senile pathological change of yellow spots, retinal vein obstruction, and the like, and has an obvious curative effect.

The invention discloses a traditional Chinese medicine for treating amblyopia eye diseases and relates to a preparation prepared from the traditional Chinese medicines as raw materials. The traditional Chinese medicine is prepared from semen cassiae, radix paeoniae alba, salvia miltiorrhiza, medlar, tuckahoe, dendrobe, kudzuvine root, tuber of dwarf lilyturf, tribulus terrestris, adenophora tetraphylla, yam, forsythia core, motherwort fruit, lophatherum gracile, antelope horn powder, glabrousleaf pittosporum seed and fructus psoraleae. The clinical use result of the traditional Chinese medicine shows that the prescription has the functions of enhancing the capability of supplying blood to caridiac muscle, promoting the blood circulation and improving the development process of eye parts of patients and promoting the repair of optic nerve and retina cells as well as the efficacies of nourishing the kidney, nourishing the liver and improving acuity of vision; the prescription can be used for treating amblyopia, hyperopia, yellow spot and other diseases caused by various reasons; and the traditional Chinese medicine has unique formula and curative effect, especially has remarkable effects for infants and juvenile patients and can ensure that the symptoms of the patients are eliminated and the visions of the patients are recovered.

A retinoscopic device, technique and scale for estimating the reflectance of the macula pigment optical density (MPOD) in normal and abnormal eyes in order to detect early pathology of the retinal pigment epithelium and photoreceptors thus screening for macular pathology the most prevalent of which is Age-related Macular Degeneration (AMD) and retinal edema and cystoid macular edema post cataract surgery.

The present inventors administered a peptide derived from VEGFR-2, which is known as one of the proteins involved in neovascularization, to model mice (A2 / Kb transgenic mice) expressing human HLA-A*0201, and tested whether or not the peptide has vaccine effect. As a result, the present inventors successfully discovered that vaccination using this peptide as an antigen is effective for inhibition of choroid neovascularization, and thereby completed the present invention. More specifically, the present invention provides vaccines for treatment and / or prevention of diseases caused by choroid neovascularization (neovascular maculopathy), which contain a VEGFR-2-derived peptide as an active ingredient.

3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses increases in retinal blood vessel permeability induced by VEGF and therefore can be used as an active component in therapeutic agents or prophylactic agents for a variety of ocular diseases to which VEGF contributes, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion, and neovascular glaucoma.

Apparatus for treating age-related macular degeneration, the apparatus comprising a light source which, in operation, serves to emit a therapeutic light beam presenting an emission wavelength lying in the range 1.2 μm to 1.3 μm, and preferably equal to 1.26 μm to 1.27 μm. The laser source preferably comprises an optical fiber Raman laser.

The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and / or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

The invention discloses a detection method for eyeground multi-disease classification based on deep learning. The method comprises the steps of obtaining an eyeground image, and selecting a training set and a test set according to independent identically-distributed conditions; preprocessing and enhancing the eyeground image, and extracting eyeground color photo image features; establishing a convolutional neural network model based on an EffecientNet + Attention Module, and adjusting the network structure; initializing network parameters by using a migration learning mode; based on the extracted eyeground features, training a detection model on a training set by using a reverse gradient propagation mode in deep learning, and finely adjusting parameters of the detection model; and finally,obtaining a detection model capable of distinguishing eight classifications including normal eyeground, high myopia, glaucoma, maculopathy, vein occlusion, diabetic retinopathy, hypertensive retinopathy and other degeneration. According to the detection method disclosed by the invention, automatic detection for multiple diseases of patients with eyeground diseases is realized, and the detection method is high in precision and high in speed.

The invention firstly discloses an application of isoflavone in preparation of a drug for treating fundus maculopathy. The present invention finds for the first time that isoflavone can significantlyreduce the degree of fundus vascular permeability and has significant effect on fundus maculopathy. The invention not only provides the new use of isoflavone, but also provides the new drug for the treatment of fundus maculopathy, which has a good application prospect in the treatment of fundus maculopathy.

The invention provides a composition for preventing and treating young garlic shoot maculopathy. The composition for preventing and treating young garlic shoot maculopathy is a wettable powder agent which comprises active components, a dispersing agent, a moistening agent and a carrier, wherein the active components comprise indoleacetic acid, fulvic acid potassium and brassinolide. The preparation method comprises steps of uniformly mixing the components according to the ratio, and subsequently crushing the components to be 300-400 meshes. Before young garlic shoots are harvested, the composition is diluted with 500-1000 times of water and then is sprayed to leaves. The composition is remarkable in preventing and treating young garlic shoot maculopathy, simple in preparation process, low in cost, good in effect, high in biological security, and capable of increasing the yield of young garlic shoots.

The invention relates to a blue-light-resistant resin lens of 1.60 in refractivity. The blue-light-resistant resin lens comprises a resin substrate of 1.60 in refractivity, a hardened film layer is dipcoated on the resin substrate, and a first SiO2 film layer, a ZrO2 film layer, a second SiO2 film layer, a Ti2O3 film layer, an In2O3 film layer and a third SiO2 film layer are sequentially deposited on the surface of the hardened film layer. The blue-light-resistant resin lens can filter 40-50% of blue light of 400-500nm in wavelength and can effectively filter blue light radiation, pricking and soreness of eyes can be reduced, eye dryness and eye fatigue can be reduced, and cataract and maculopathy can be prevented.

The invention provides a medicine for preventing oxidative stress of retinal ganglion, which is a preparation prepared by taking DNA tetrahedron as active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients. The invention also provides the use of the DNA tetrahedron in the preparation of medicines for preventing oxidative stress and apoptosis of retinal ganglion cells. The use of tFNA to prepare drugs for preventing oxidative stress of retinal ganglion cells will help to treat diseases caused by oxidative stress of retinal ganglion cells including glaucoma, and has a very good application prospect.

The invention provides a dual-target fusion protein, which contains VEGF receptors and cell membrane fragments of PDGF beta receptors. Through the optimized combination of functional fragments, the present invention improves the binding ability of the fusion protein and the dual-target VEGF and PDGF β, can effectively inhibit the proliferation of new blood vessels, and achieve the treatment of neovascular proliferation diseases related to VEGF and PDGF β, such as tumor and wet age-related macular degeneration (AMD).

The invention discloses nutrition capsules for treating senile maculopathy and a preparation process, which relate to the field of medical and health-care foods. The capsules consist of capsule materials and capsule contents and are prepared from 1 to 20 milligrams of xanthophylls, 0.1 to 2 milligrams of zeaxanthin, 0.05 to 1 milligrams of vitamin A, 0.2 to 4 milligrams of gluconate zinc, 0.2 to 4 milligrams of selenium, 0.5 to 10 milligrams of taurine and 200 to 250 milligrams of dried skim milk. The preparation process comprises: weighing raw materials, mixing the raw materials, granulating the mixture, drying the grains, straightening the grains, filling the grains and packaging the grains to obtain the finished products. The xanthophylls of the capsules are easy to be absorbed by human bodies, the bioavailability is high and the properties of the capsules are stable.

Apparatus and methods to improve the vision in a person with a macular disease, comprising the purposeful temporary creation of increased corneal optical aberrations. Strategies include corneal treatment patterns that are one or more of asymmetric, decentered or eccentric with respect to the visual axis, which would result in worsening vision in a normal eye but surprisingly become sight enhancing in a patient with the loss of foveal function due to macular disease.

The invention provides a method and reagent kit for detecting eye microorganisms, and an application of the reagent kit to diagnosis of age-related macular degeneration. The method for detecting eye microorganisms is a metagenome sequencing method and / or a real-time fluorescent quantitation PCR method. The invention further provides a medicine for killing or restraining microorganisms to treat theage-related macular degeneration, and a new method is provided for treatment of the age-related macular degeneration.

The invention discloses a medicine fusion specifically bound with human angiopoietin-2, and also discloses a preparation method of the medicine fusion and a method for treating senile maculopathy, tumors, inflammatory diseases and endometriosis by using the medicine fusion.

The invention discloses a gene medicine for preventing and treating neovascular eye diseases. The invention relates to the technical field of gene medicines, in particular to a recombinant vector which comprises a PEDF or PEDF functional fragment gene and a shRNA fragment targeting human VEGFA (vascular endothelial growth factor A). The invention also provides application of the recombinant vector in preparation of medicines for preventing or treating angiogenesis-related eye diseases. The PEDF overexpression and VEGFA interference adeno-associated virus involved in the invention can interfere with the expression level of the VEGFA in vascular endothelial cells, effectively down-regulate the protein level of the VEGFA, further inhibit the proliferation and migration activity of the vascular endothelial cells, and inhibit the angiogenesis ability of the vascular endothelial cells, so that a new target and approach for the treatment of wet maculopathy is provided.

The invention belongs to the fields of molecular biology, biochemistry and etiology, and discloses an APE1 inhibitor and application thereof in the preparation of drugs for the treatment of tumors and vascular poliferative diseases. The APE1 inhibitor has a structure shown in a following formula 1, by inhibiting the activity of the redox end of APE1, the formation process of tumors is inhibited from several aspects at the same time, compared with an existing APE1 inhibitor E3330, it is presented that the APE1 inhibitor is lower in cytotoxicity and has higher antiviral activity, antiangiogenic activity and anti-cell invasion activity and the like. The APE1 inhibitor has great application prospects on the treatment of various malignant tumors such as Kaposi's sarcoma, osteosarcoma, pancreatic cancers, bladder cancers, ovarian cancers and other cancers, and other abnormal vascular proliferative diseases such as age-related macular degeneration. The formula 1 is shown in the description.

The invention discloses an isoflavone eye drop liquid and a preparation method and an application thereof. The isoflavone eye drop liquid includes the following components: 0.001%-0.1% (w / v) of soy isoflavones, 0.3-0.7% (w / v) of a cosolvent, 0.001%-0.1% (w / v) of an antibacterial agent, 0.1%-2% (w / v) of [belta]-nicotinamide mononucleotide, an osmotic pressure regulator, a pH regulator, with the balance being injection water. The eye drop liquid of the invention has good efficacy of inhibiting ocular tumors of children such as retinoblastoma and ocular neovascularization such as fundus maculopathy, has no stimulus, is safe, is high in stability, and has great application prospects.

The invention relates to a medical health care product for resisting antioxidation, delaying aging and preventing age-related macular degeneration, and a preparation method thereof. The traditional Chinese medicine and health care product composition comprises the following components by weight: 15-25 parts of astaxanthin and 6-14 parts of lutein. The composition is supplemented with auxiliaries acceptable in preparation process and can be prepared into hard capsule, soft capsule, oral liquid and other oral preparation. The composition uses astaxanthin and lutein as raw materials, aims at the physical features and diet culture of Chinese, is subjected to scientific quantitative ratio to maximizes the synergic effects of resisting antioxidation, delaying aging and preventing age-related macular degeneration; and the action characteristics of the two varieties complement each other, so that the composition has the comprehensive and obvious effects of resisting antioxidation, delaying aging and preventing age-related macular degeneration.

The invention belongs to the technical field of light feeding instruments, and discloses a light feeding instrument with adjustable treatment intensity, which comprises a bottom support assembly, a red light generation assembly, a lens cone assembly and a control unit. The bottom supporting assembly is used for forming an installation foundation of the treatment-intensity-adjustable nursing light instrument, the bottom supporting assembly comprises a base, a hollow supporting column and a supporting rod, the base is horizontally arranged, the hollow supporting column is vertically and fixedly installed on the upper portion of the base, and the supporting rod is installed in the upper end of the hollow supporting column through an adjusting bolt; the red light generating assembly is used for generating red light. According to the light feeding instrument with the adjustable treatment intensity, the intensity of the generated treatment red light is adjustable, the requirement for myopia treatment of myopia patients with different myopia degrees can be met, the treatment effect is good, and the use limitation is effectively eliminated; more importantly, the risk of fundus lesion, maculopathy and other potential side effects caused by overhigh red light intensity or long-time use can be reduced.

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and / or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.

The invention relates to the technical field of biology, and particularly discloses application of a small molecule compound composition in preparation of a medicine for preventing and treating retinal injury diseases. The small molecule compound composition effectively antagonizes cell death and dysfunction caused by oxidative stress on retinal pigment epithelial cells, and can effectively protect the retinal pigment epithelial cells so as to protect the structural integrity and normal function of the whole retinal layer cells; the compound can be used for preventing and potentially treating retinal injury caused by oxidative stress, and is particularly favorable for preventing and / or treating age-related maculopathy and other retinal injury diseases. Besides, experiments prove that the small molecule compound composition has no obvious pharmacological toxicity and can effectively control occurrence and development of retinal injury diseases, and a new theoretical support is provided for development of unknown biological activity and future clinical treatment effects of the small molecule compound composition.

The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and / or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

The invention provides a maculopathy eyesight evaluation method, which comprises a maculopathy visual chart device with action instruction control, and the maculopathy visual chart device comprises aneyesight screen, a control unit, a keyboard, an action sensor and a network module. The keyboard is used for inputting key signals. The network module is used for connecting a computer and a network.The action sensor is used for sensing and outputting an action instruction signal of a user. The eyesight screen is used for displaying test characters with different gray levels, different sizes anddifferent contrast ratios. The eyesight screen does not need backlight and does not emit light by itself, and displayed content is visible through reflected light. The device obtains the vision evaluation SF through the calculation of a test distance S, a screen size P, an area number M, a flexible value L, a size level D*1, a background gray level Hd1, a character gray level Db1 and a inverse color coefficient F. The invention provides a comprehensive evaluation method aiming at the visual sensitivity characteristic of a maculopathy patient, and aims to evaluate the vision level of the maculopathy patient more reasonably.